Cite
HARVARD Citation
Califano, R. et al. (n.d.). Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial. Lung cancer. pp. S59-S60. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Califano, R. et al. (n.d.). Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial. Lung cancer. pp. S59-S60. [Online].